Prohibits step therapy delays for insulin drugs

File SF2071 ("Prohibits step therapy delays for insulin drugs") is before the Minnesota Legislature and has not been decided. Latest step (March 9, 2026): Comm report: To pass and re-referred to.

Minnesota file SF2071, before the Minnesota Legislature. Still to be decided as of 2026-03-09.

What it does

Insulin patients skip insurer pre-approval waiting periods Patients prescribed insulin will receive their medication without step therapy protocols requiring them to try cheaper alternatives first, eliminating delays that can be dangerous for diabetics.

The bigger picture

May increase insulin costs for health insurers statewide By removing insurer cost-containment tools for insulin, health plans may face higher pharmacy costs, potentially raising premiums or reducing coverage for other populations.

What to watch

Non-insulin diabetes medications still subject to step therapy The prohibition applies only to insulin; patients on other diabetes drugs or conditions remain eligible for step therapy protocols, leaving coverage variability intact for much of the diabetic population.

Official summary

Step therapy use protocol for insulin drugs prohibition

Read the official record for SF2071

See everything up for a vote · This week in Minnesota · See what we have filed with the clerk